导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -1.46% | 2819/4773 |
| 近一周 | -1.37% | 2082/5465 |
| 近一月 | -3.03% | 2110/5421 |
| 近一季 | -6.52% | 2443/5231 |
| 近半年 | -3.11% | 2396/4920 |
| 近一年 | 0.25% | 2731/4394 |
| 近两年 | 40.64% | 1873/2954 |
| 近三年 | 22.41% | 1402/2253 |
| 成立以来 | 79.26% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-3.16% 3061/4961 |
11.31% 2347/5312 |
- - |
- - |
| 2025 | 17.48% 2380/4813 |
-1.05% 2553/3635 |
1.58% 2272/4076 |
16.94% 2578/4524 |
-0.05% 2325/4813 |
| 2024 | 12.64% 1224/3463 |
1.88% 849/2808 |
-1.57% 1078/3014 |
15.03% 1837/3129 |
-2.35% 2051/3463 |
| 2023 | -9.77% 1227/2656 |
3.69% 1147/2280 |
-4.73% 1269/2385 |
-3.11% 851/2515 |
-5.73% 1480/2655 |
| 2022 | -16.83% 518/2207 |
-12.96% 674/1919 |
6.88% 584/2016 |
-11.71% 566/2113 |
1.26% 1321/2208 |
| 2021 | 8.39% 479/1822 |
-1.97% 565/1255 |
8.48% 619/1330 |
-1.25% 513/1466 |
3.22% 460/1822 |
| 2020 | 33.54% 455/1250 |
-7.28% 536/1028 |
14.37% 555/1067 |
11.21% 469/1164 |
13.23% 377/1184 |
| 2019 | 34.48% 402/1092 |
25.01% 485/739 |
-0.11% 211/788 |
0.88% 448/850 |
6.74% 556/918 |
| 2018 | - - |
- - |
- - |
0.47% 152/660 |
-8.76% 108/682 |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 景顺长城中证港股通创新药ETF | 1.6507 | 28.23% |
| 港股医疗 | 0.9366 | 28.18% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 港股通医疗ETF工银 | 0.9464 | 28.06% |
| 港股通医疗ETF华宝 | 0.9577 | 27.97% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2844 | 27.92% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 万家中证港股通创新药ETF发起式联接A | 1.3863 | 27.32% |
| 万家中证港股通创新药ETF发起式联接C | 1.3856 | 27.27% |
| 建信MSCI联接A VS. 长安沪深300非周期A(740101) |